TRACON Pharmaceuticals Announces TRC105 Clinical Data Presentation at Upcoming AACR Annual Meeting

SAN DIEGO, April 11, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that TRC105 prostate cancer-related clinical data will be presented at the upcoming American Association for Cancer Research (AACR) annual meeting to be held April 16-20, 2016, in New Orleans, LA.

Dr. Liang Cao and colleagues at the National Cancer Institute will present a poster featuring data from a previous clinical study of TRC105 in prostate cancer. The presentation details are as follows:

Abstract Number: 2048
Abstract Title: Pharmacodynamic biomarker studies of TRC105 anti-endoglin (CD105) antibody revealed anti-angiogenic activity associated with CD105 depletion
Presenter: Liang Cao, Ph.D., National Cancer Institute, Bethesda, MD
Location: Section 14, Poster Board Number 20
Date: Monday, April 18, 2016
Time: 1:00pm – 5:00pm CDT

The poster will be available on the Company’s website.

About TRC105

TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis. For more information about the clinical trials, please visit TRACON’s website at


TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at

Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987

Source:TRACON Pharmaceuticals, Inc.